150 related articles for article (PubMed ID: 24875783)
1. The continual reassessment method for multiple toxicity grades: a bayesian model selection approach.
Pan H; Zhu C; Zhang F; Yuan Y; Zhang S; Zhang W; Li C; Wang L; Xia J
PLoS One; 2014; 9(5):e98147. PubMed ID: 24875783
[TBL] [Abstract][Full Text] [Related]
2. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials.
Pan H; Yuan Y
Stat Med; 2017 Jan; 36(2):266-279. PubMed ID: 26991076
[TBL] [Abstract][Full Text] [Related]
3. The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach.
Yuan Z; Chappell R; Bailey H
Biometrics; 2007 Mar; 63(1):173-9. PubMed ID: 17447942
[TBL] [Abstract][Full Text] [Related]
4. Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data.
James GD; Symeonides SN; Marshall J; Young J; Clack G
BMC Cancer; 2016 Aug; 16(1):703. PubMed ID: 27581751
[TBL] [Abstract][Full Text] [Related]
5. Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method.
Daimon T; Zohar S; O'Quigley J
Stat Med; 2011 Jun; 30(13):1563-73. PubMed ID: 21351288
[TBL] [Abstract][Full Text] [Related]
6. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
James GD; Symeonides S; Marshall J; Young J; Clack G
BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
[TBL] [Abstract][Full Text] [Related]
7. Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities.
Ezzalfani M; Zohar S; Qin R; Mandrekar SJ; Deley MC
Stat Med; 2013 Jul; 32(16):2728-46. PubMed ID: 23335156
[TBL] [Abstract][Full Text] [Related]
8. Critical aspects of the Bayesian approach to phase I cancer trials.
Neuenschwander B; Branson M; Gsponer T
Stat Med; 2008 Jun; 27(13):2420-39. PubMed ID: 18344187
[TBL] [Abstract][Full Text] [Related]
9. Calibration of prior variance in the Bayesian continual reassessment method.
Lee SM; Cheung YK
Stat Med; 2011 Jul; 30(17):2081-9. PubMed ID: 21413054
[TBL] [Abstract][Full Text] [Related]
10. Adaptive prior variance calibration in the Bayesian continual reassessment method.
Zhang J; Braun TM; Taylor JM
Stat Med; 2013 Jun; 32(13):2221-34. PubMed ID: 22987660
[TBL] [Abstract][Full Text] [Related]
11. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
Paoletti X; Kramar A
Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
[TBL] [Abstract][Full Text] [Related]
12. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
Chen Z; Tighiouart M; Kowalski J
Contemp Clin Trials; 2012 Sep; 33(5):949-58. PubMed ID: 22561391
[TBL] [Abstract][Full Text] [Related]
13. Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.
Zhao D; Zhu J; Wang L
Contemp Clin Trials; 2021 Mar; 102():106265. PubMed ID: 33418097
[TBL] [Abstract][Full Text] [Related]
14. The continual reassessment method in cancer phase I clinical trials: a simulation study.
Chevret S
Stat Med; 1993 Jun; 12(12):1093-108. PubMed ID: 8210815
[TBL] [Abstract][Full Text] [Related]
15. Accuracy, Safety, and Reliability of Novel Phase I Trial Designs.
Zhou H; Yuan Y; Nie L
Clin Cancer Res; 2018 Sep; 24(18):4357-4364. PubMed ID: 29661774
[TBL] [Abstract][Full Text] [Related]
16. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials.
Ishizuka N; Ohashi Y
Stat Med; 2001 Sep 15-30; 20(17-18):2661-81. PubMed ID: 11523075
[TBL] [Abstract][Full Text] [Related]
17. [Continual reassessment method (CRM)].
Ishizuka N
Gan To Kagaku Ryoho; 2000 Aug; 27(9):1449-57. PubMed ID: 10969605
[TBL] [Abstract][Full Text] [Related]
18. A hybrid Bayesian adaptive design for dose response trials.
Chang M; Chow SC
J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
[TBL] [Abstract][Full Text] [Related]
19. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.
Bayar MA; Ivanova A; Le Teuff G
Comput Methods Programs Biomed; 2019 Jul; 176():211-223. PubMed ID: 31200907
[TBL] [Abstract][Full Text] [Related]
20. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
Horton BJ; Wages NA; Conaway MR
Stat Med; 2017 Jan; 36(2):291-300. PubMed ID: 27435150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
